Although ginsenoside Rg3 has been shown to exert anticancer effects in various malignancies, the effects and molecular mechanisms of ginsenoside Rg3 in cervical cancer (CC) remain unclear. This study explored the effect of ginsenoside Rg3 on CC development at the cellular level. The effect of ginsenoside Rg3 on cell proliferation was measured using colony formation and Cell Counting Kit-8 assays. Migration, invasion, and in vitro angiogenesis of CC cells were detected using wound healing, transwell, and tube formation assays, respectively. In addition, we explored the target genes and molecular mechanisms of ginsenoside Rg3 in CC cells overexpressing AKT serine/threonine kinase 2 (AKT2). The results indicated that ginsenoside Rg3 suppressed proliferation, migration, invasion, and tube formation of CC cells in vitro. In addition, ginsenoside Rg3 treatment decreased the expression of AKT2 in CC cells. Moreover, ginsenoside Rg3 treatment partially reversed AKT2 overexpression-mediated reduction in cell proliferation, migration, invasion, and tube formation. In conclusion, the above findings suggested that ginsenoside Rg3 inhibits CC progression via regulation of AKT2 expression, which might provide a potential therapeutic target for tumor therapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469050PMC
http://dx.doi.org/10.1016/j.heliyon.2023.e19045DOI Listing

Publication Analysis

Top Keywords

ginsenoside rg3
40
migration invasion
12
tube formation
12
ginsenoside
10
rg3
9
rg3 inhibits
8
cervical cancer
8
akt2 expression
8
molecular mechanisms
8
mechanisms ginsenoside
8

Similar Publications

This study investigates the synergistic inhibitory effects of combining the stimulator of interferon genes (STING) agonist cyclic diadenylate monophosphate (c-di-AMP) and ginsenoside RG3 on cisplatin (DDP)-resistant gastric cancer (GC) cells. The objective is to identify novel therapeutic targets and offers insights for the clinical management of DDP resistance. Various techniques were employed, including western blot, MTT assay, colony formation assay, scratch assay, transwell assay, tubule formation assay, flow cytometry, Hoechst 33342 fluorescence staining, and in vivo experiments, to investigate the potential mechanisms and effects of the combined application of the STING agonist and ginsenoside RG3 in reversing cisplatin resistance in gastric cancer.

View Article and Find Full Text PDF

Osteoporosis is mainly caused by an imbalance in osteoclast and osteoblast regulation, resulting in an imbalance in bone homeostasis. Ginsenoside Rg3 (Rg3) has been reported to have a therapeutic effect on alleviating osteoporosis. Nonetheless, the underlying mechanisms have not been completely elucidated.

View Article and Find Full Text PDF

Cancer is one of the most devastating illnesses in the world, impacting millions of individuals every year. Despite various therapies, the final effect is unsatisfactory. Chemotherapy currently dominates as the primary option of treatment.

View Article and Find Full Text PDF

Targeting cardiolipin metabolism for Parkinson's disease therapy.

Metabol Open

December 2024

Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias, Goudi, 11527, Athens, Greece.

View Article and Find Full Text PDF

The formation of inclusion complexes between Ginsenoside Rg3 and cyclodextrins represents a promising strategy to enhance the solubility of G-Rg3. Nevertheless, the molecular mechanisms underlying the interaction between G-Rg3 and cyclodextrins have yet to be fully elucidated. In this study, we employed a combination of molecular simulation and experimental methodologies to identify the most effective solubilizing carriers among G-Rg3, β-cyclodextrin (β-CD), 2-hydroxypropyl-β-cyclodextrin (HP-β-CD), and 2,6-dimethyl-β-cyclodextrin (DM-β-CD).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!